ArticleOncology letters2025
Utility of the CPS + EG score with real-life data in patients with breast cancer undergoing neoadjuvant chemotherapy.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common type of cancer in women, and predicting disease progression through CPS and EG scoring is important for treatment and prognosis, especially after neoadjuvant chemotherapy. The present study aimed to evaluate the association between the clinical and pathological stage (CPS) + estrogen receptor status and histologic grade (EG) score and disease-free survival (DFS) and overall survival (OS) in patients with breast cancer undergoing neoadjuvant chemotherapy. Data from 148 patients with breast cancer who were treated with neoadjuvant chemotherapy in the Medical Oncology Clinic of Izmir Tepecik Training and Research Hospital between 2013-2018 were analyzed. The following variables were assessed: Demographic characteristics, tumor size, clinical staging, estrogen receptor status, tumor nuclear grade in biopsy material and postoperative pathological staging. CPS + EG scores were calculated using simultaneous estrogen receptor status and tumor nuclear grade parameters, which were developed using the Neoadjuvant Therapy Outcomes Calculator Software of the MD Anderson Cancer Center. The 5-year OS and DFS rates were evaluated, and the 5-year follow-up of the patients was analyzed. The median follow-up period was 76.5 months, and the median survival time was 104.1 months. The pathological complete response (pCR) rate was 23.6%. Patients with a pCR were revealed to have a significantly higher DFS rate compared with the non-pCR group (P=0.038). A significant decline in DFS was also demonstrated with increasing CPS + EG scores (P<0.001). Moreover, a CPS score of 3-4 (P<0.001) and a CPS + EG score of 3-4-5 (P<0.001) were significantly associated with a worse OS. In conclusion, the relationship between the CPS + EG score and survival is apparent in the real-world data in the present study. As the score increases, both the probability of recovery and OS decrease. Furthermore, the CPS + EG scoring system is an easy, free and accessible method to estimate prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.